Am. J. Respir. Crit. Care Med., Volume 157, Number 3, March 1998, 853-857

Therapeutic Effect of Erythromycin on Influenza Virus-induced Lung Injury in Mice

KEIZO SATO, MORITAKA SUGA, TAKAAKI AKAIKE, SHIGEMOTO FUJII, HIROYUKI MURANAKA, TOSHINORI DOI, HIROSHI MAEDA, and MASAYUKI ANDO

First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine, Kumamoto, Japan

Erythromycin (EM) is an antibiotic with potent antiinflammatory effects that is used for treating chronic lower respiratory tract infections. It has been shown that free radicals, such as the superoxide anion and nitric oxide (NO), are pathogenic molecules in viral disease. Much attention has been given to a critical role of NO in the pathologic events of various inflammatory diseases. In the present study, we evaluated the effects of EM on influenza-virus-induced pneumonia in mice infected with a lethal dose of influenza virus A/Kumamoto/Y5/67 (H2N2). The administration of EM at a dose of 3.3 mg/kg/d (intraperitoneally, from Days 1 to 6 after infection), significantly improved the survival rate of mice infected with influenza virus, and the survival rate of the virus-infected mice at Day 20 after infection increased in a dose-dependent fashion with EM administered to the animals, from 14% among controls to 42% among animals given EM at 1.0 mg/kg/d and 57% among those given EM at 3.3 mg/kg/d. The induction of interferon- (IFN-) in the mouse lung was inhibited by EM treatment on Day 6 after infection. Simultaneously, the number of inflammatory cells recovered in lung lavage fluid 6 d after virus infection was significantly reduced by the treatment with EM. The EM treatment resulted in a dose-dependent decrease in the level of nitrite/nitrate (metabolites of NO) in the serum and the NO synthase (NOS)-inducting potential in the lungs of the virus-infected mice. These results indicate that EM may have substantial therapeutic value for various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing NO overproduction in the lung.

This article has been cited by other articles:

				M. Oda, A. Kihara, H. Yoshioka, Y. Saito, N. Watanabe, K. Uoo, M. Higashihara, M. Nagahama, N. Koide, T. Yokochi, et al. Effect of Erythromycin on Biological Activities Induced by Clostridium perfringens {alpha}-Toxin J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 934 - 940. [Abstract] [Full Text] [PDF]

				T. Itoh, H. Obata, S. Murakami, K. Hamada, K. Kangawa, H. Kimura, and N. Nagaya Adrenomedullin ameliorates lipopolysaccharide-induced acute lung injury in rats Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L446 - L452. [Abstract] [Full Text] [PDF]

				J. P. Jayasekera, C. G. Vinuesa, G. Karupiah, and N. J. C. King Enhanced antiviral antibody secretion and attenuated immunopathology during influenza virus infection in nitric oxide synthase-2-deficient mice. J. Gen. Virol., November 1, 2006; 87(Pt 11): 3361 - 3371. [Abstract] [Full Text] [PDF]

				M. Desaki, H. Okazaki, T. Sunazuka, S. Omura, K. Yamamoto, and H. Takizawa Molecular Mechanisms of Anti-Inflammatory Action of Erythromycin in Human Bronchial Epithelial Cells: Possible Role in the Signaling Pathway That Regulates Nuclear Factor-{kappa}B Activation Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1581 - 1585. [Abstract] [Full Text] [PDF]

				K. SATO, M. B. KADIISKA, A. J. GHIO, J. CORBETT, Y. C. FANN, S. M. HOLLAND, R. G. THURMAN, and R. P. MASON In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS FASEB J, November 1, 2002; 16(13): 1713 - 1720. [Abstract] [Full Text] [PDF]

				T. Suzuki, M. Yamaya, K. Sekizawa, M. Hosoda, N. Yamada, S. Ishizuka, A. Yoshino, H. Yasuda, H. Takahashi, H. Nishimura, et al. Erythromycin Inhibits Rhinovirus Infection in Cultured Human Tracheal Epithelial Cells Am. J. Respir. Crit. Care Med., April 15, 2002; 165(8): 1113 - 1118. [Abstract] [Full Text] [PDF]

				T. Suzuki, M. Yanai, M. Yamaya, T. Satoh-Nakagawa, K. Sekizawa, S. Ishida, and H. Sasaki Erythromycin and Common Cold in COPD Chest, September 1, 2001; 120(3): 730 - 733. [Abstract] [Full Text] [PDF]

				M. Tsurita, M. Kurokawa, M. Imakita, Y. Fukuda, Y. Watanabe, and K. Shiraki Early Augmentation of Interleukin (IL)-12 Level in the Airway of Mice Administered Orally with Clarithromycin or Intranasally with IL-12 Results in Alleviation of Influenza Infection J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 362 - 368. [Abstract] [Full Text]

				H. NAKANO, H. IDE, M. IMADA, S. OSANAI, T. TAKAHASHI, K. KIKUCHI, and J. IWAMOTO Reduced Nasal Nitric Oxide in Diffuse Panbronchiolitis Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2218 - 2220. [Abstract] [Full Text]